BridgeBio Pharma Inc. (US10806X1028)
Summary
US10806X1028 Chart
BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews
BridgeBio Pharma maintains a "Strong Buy" rating, driven by robust revenue growth and multiple late-stage pipeline catalysts. The company delivered Q2 2026 net revenues of $243.7M, up from the prior year's $110.6M, outperforming despite competition. Three NDA submissions—BBP-418, oral infigratinib, and encaleret—are under Priority Review, with PDUFA dates spanning late 2026 to mid-2027.
BridgeBio Pharma, Inc. (BBIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
BridgeBio Pharma, Inc. (BBIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
BridgeBio Pharma, Inc. (BBIO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
BridgeBio Pharma, Inc. (BBIO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
BridgeBio Pharma Inc. (US10806X1028) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BridgeBio Pharma Inc. ever had a stock split?
BridgeBio Pharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Neil Kumar CEO | XSTU Exchange | US10806X1028 ISIN |
| US Country | 999 Employees | - Last Dividend | - Last Split | 27 Jun 2019 IPO Date |
Overview
BridgeBio Pharma, Inc. stands as a prominent figure in the commercial-stage biopharmaceutical sector, dedicated to developing groundbreaking medicines aimed at treating genetic diseases and cancers. Since its inception in 2015, the company has been at the forefront of medical research, leveraging advanced scientific methods to discover, create, test, and deliver transformative treatments. Operating out of Palo Alto, California, BridgeBio Pharma is fuelled by collaborations and license agreements with esteemed institutions such as the Leland Stanford Junior University and Leidos Biomedical Research, Inc. Through its relentless pursuit of medical innovation, BridgeBio Pharma strives to offer new hope to patients facing some of the most challenging medical conditions.
Products and Services
- AG10
This compound is a next-generation oral small molecule designed to be a near-complete TTR stabilizer. Currently in Phase 3 clinical trials, AG10 targets the treatment of TTR amyloidosis or transthyretin amyloid cardiomyopathy (ATTR-CM), a significant advancement in addressing this condition.
- Low-dose Infigratinib
An oral FGFR1-3 selective tyrosine kinase inhibitor, low-dose infigratinib is under a Phase 3 double-blinded, placebo-controlled pivotal study. It represents a potential treatment option for children with achondroplasia, showcasing BridgeBio Pharma’s commitment to addressing rare genetic growth disorders.
- BBP-631
BridgeBio Pharma is advancing BBP-631, an AAV5 gene transfer product candidate, through a Phase 1/2 clinical trial. This innovative therapy targets congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD), offering a novel gene therapy approach to this adrenal disorder.
- Encaleret
A small molecule antagonist of the calcium sensing receptor (CaSR), Encaleret is currently in a phase 3 clinical trial. This product aims to treat autosomal dominant hypocalcemia type 1 (ADH1), underscoring the company's focus on developing treatments for rare metabolic disorders.
- BBP-418
In Phase 3 clinical trial, BBP-418 is a glycosylation substrate pro-drug for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). This highlights BridgeBio Pharma’s commitment to combating muscular dystrophies through cutting-edge therapies.
Contact Information
